Global Interleukin Inhibitors Market Analysis & Forecast 2019-2023 - Featuring Eli Lilly & Co, Roche, Johnson & Johnson Services, Novartis, and Regeneron Pharmaceuticals - ResearchAndMarkets.com

DUBLIN--()--The "Interleukin Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The Interleukin inhibitors market analysis considers sales from Interleukin-23 inhibitors, Interleukin-17 inhibitors, Interleukin-6 inhibitors, and other Interleukin inhibitors. The analysis also considers the sales of Interleukin inhibitors in Asia, Europe, North America, and RoW.

In 2018, the Interleukin-23 inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of psoriasis and improved R&D on Interleukin-23 inhibitors will help in the growth of Interleukin-23 inhibitors segment and maintain its market position.

Also, the global Interleukin inhibitors market report looks at factors such as high target affinity and specificity of Interleukin inhibitors, recent approvals and robust pipeline, and presence of reimbursement and patient assistance program. However, availability of substitutes, product withdrawals and failure of clinical trials, and adverse side effects and high cost of Interleukin inhibitors may hamper the growth of the Interleukin inhibitors industry over the forecast period.

High target affinity and specificity of Interleukin inhibitors

Interleukin inhibitors are target specific and work directly in Interleukin receptors. These drugs are highly effective in the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis, and Crohn's disease. Higher patient adherence to these drugs because of their higher affinity and specificity. The advances in the R&D Interleukin drugs and clinical trials for late-stage molecules is expected to lead the expansion of the global Interleukin inhibitors market at a CAGR of almost 13% during the forecast period.

Increasing awareness about autoimmune diseases

The major focus of the awareness programs is to educate people about the symptoms of various arthritis indications, cause of the diseases, risk factors that cause inflammation, availability of various treatments and preventive measures that can be taken to control the disease. These awareness campaigns are expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global Interleukin inhibitors market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Interleukin inhibitors manufacturers, that include:

  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

Also, the Interleukin inhibitors analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • Interleukin-23 inhibitors - Market size and forecast 2018-2023
  • Interleukin-17 inhibitors - Market size and forecast 2018-2023
  • Interleukin-6 inhibitors - Market size and forecast 2018-2023
  • Other Interleukin inhibitors - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

  • Increasing awareness about autoimmune diseases
  • Strategic alliances
  • Introduction of biosimilars

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/lomefw

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900